Enzymatic activation of a doxorubicin-peptide prodrug by prostate- specific antigen

Cancer Research

Volumn 58, Issue 12, 1998, Pages 2537-2540

  Denmeade, Samuel R ^a   Nagy, Attila ^c   Gao, Jin ^a   Lilja, Hans ^d   Schally, Andrew V ^c   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DOXORUBICIN; PEPTIDE; PRODRUG; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; HUMANS; MALE; PRODRUGS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032526152     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Yagoda, A., and Petrylak, D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer, 71: 1098-1109, 1993.
2. Denmeade, S. R., and Isaacs, J. T. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. J. T. Thomas, M. W. Anders, F. Murad, and J. T. Coyle (eds.), In: (Advances in Pharmacology) Vol. 35, pp. 281-306. New York Academic Press, Inc., 1996.
3. Denmeade, S. R., Nagy, A., Schally, A., and Isaacs, J. T. Enzymatic activation of a doxorubicin prodrug by prostate-specific antigen. Proc. Am. Assoc. Cancer Res., 39: 3765, 1998.
4. Newling, D. W. W. The use of Adriamycin and its derivatives in the treatment of prostatic cancer. Cancer Chemother. Pharmacol., 30 (Suppl.): S90-S94, 1992.
5. Sella, A., Kilbourn, R., Amato, R., Bui, C., Zukiwski, A. A., Ellerhorst, J., and Logothetis, C. J. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J. Clin. Oncol., 12: 683-688, 1994.
6. Wang, M. C., Valenzuela, L. A., Murphy, G. P., and Chu, T. M. Purification of a human prostate specific antigen. Invest. Urol., 17: 159-163, 1979.
7. Watt, K. W. K., Lee, P-J., M'Timkulu, T., Chan, W-P., and Loor, R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc. Natl. Acad. Sci. USA, 83: 3166-3170, 1986.
8. Christensson, A., Laurell, C-B., and Lilja, H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine protease inhibitors. Eur. J. Biochem., 194: 755-765, 1990.
9. Lilja, H., Abrahamsson, P-A., and Lundwall, A. Semenogelin, the predominant protein in human semen. J. Biol. Chem., 264: 1894-1900, 1989.
10. Akiyama, K., Nakamura, T., Iwanaga, S., and Hara, H. The chymotrypsin-like activity of human prostate-specific antigen γ-seminoprotein. FEBS Lett., 225: 1894-1900, 1987.
11. Denmeade, S. R., Lou, W., Malm, J., Lövgren, J., Lilja, H., and Isaacs, J. T. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate specific antigen. Cancer Res., 57: 4920-4926, 1997.
12. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J., Rosenthal, H., Chu, T. M., Mirand, E. A., and Murphy, G. P. LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1980.
13. Iizumi, T., Yazaki, T., Kanoh, S., Kondo, I., and Koiso, K. Establishment of a new prostatic carcinoma cell line (TSU-Pr1). J. Urol., 137: 1304-1306, 1987.
14. Hoehn, W., Schroeder, F. H., Riemann, J. F., Joebsis, A. C., and Hermanek, P. Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC-82). Prostate 1: 94-104, 1980.
15. Berges, R. R., Vukanovic, J., Epstein, J. I., CarMichael, M., Cisek, L., Johnson, D. E., Veltri, R. W., Walsh, P. C., and Isaacs, J. T. Implications of the cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer. Res., 1: 473-480, 1995.
16. Lövgren, J., Piironen, T., Overmo, C., Dowell, B., Karp, M., Pettersson, K., Lilja, H., and Lundwall, A. Production of recombinant PSA and hk2 and analysis of their immunologic cross-reactivity. Biochem. Biophys. Res. Commun., 213: 888-895, 1995.
17. DeJong, J., Geijssen, G. J., Munniksma, C. N., Vermorken, J. B., and Van der Vijgh, W. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-L-leucyldoxorubicin and its metabolites in a Phase I clinical trial. J. Clin. Oncol., 10: 1897-1906, 1992.
18. Martikainen, P., Kyprianou, N., Tucker, R. W., and Isaacs, J. T. Programmed death of nonproliferating androgen independent prostatic cancer cells. Cancer Res., 51: 4693-4700, 1991.
19. 1-antichymotrypsin. Clin. Chem., 37: 1618, 1991.
20. 2-macroglobulin receptor/LDL receptor-related protein. J. Urol., 159: 297-303, 1998.
21. DeJong, J., Klein, I., Bast, A., and Van der Vijgh, W. Analysis and pharmacokinetics of N-L-leucyldoxorubicin and metabolites in tissues of tumor-bearing BALB/c mice. Cancer Chemother. Pharmacol., 31: 156-160, 1992.
22. Deprez-deCampeneere, D., Baurain, R., and Trouet, A. Accumulation and metabolism of new anthracycline derivatives in the heart after IV injection into mice. Cancer Chemother. Pharmacol. 8: 193-197, 1982.
23. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res., 51: 222-226, 1991.